Evidence map›Paper›PMID 26523107›Full record

ReviewWorld journal of gastroenterology2015

Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge.

Simon Pernot, Thibault Voron, Geraldine Perkins, Christine Lagorce-Pages, Anne Berger, Julien Taieb

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03620643 (Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours), which is not on this map. Cited by 207 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
207citing papers in PubMed, 4 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03620643 phase2completednot on this mapstarted 2019, after this paper: background citation

Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

TypeinterventionalSponsorRoyal Marsden NHS Foundation TrustRan2019 to 2024Enrolled33ConditionsLobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene MutationArmsCrizotinib Oral Capsule [Xalkori], Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]
3 · Its place in the literature

Who cites it

207 citing papers in PubMed, 4 syntheses or guidelines pooled it, 311 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Trial
  6. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021
    Trial
  7. Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2020
    Trial
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

147 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Simon PernotSimon Pernot, Geraldine Perkins, Julien Taieb, Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Paris Descartes, Sorbonne Paris Cité, France.
Thibault VoronSimon Pernot, Geraldine Perkins, Julien Taieb, Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Paris Descartes, Sorbonne Paris Cité, France.
Geraldine PerkinsSimon Pernot, Geraldine Perkins, Julien Taieb, Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Paris Descartes, Sorbonne Paris Cité, France.
Christine Lagorce-PagesSimon Pernot, Geraldine Perkins, Julien Taieb, Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Paris Descartes, Sorbonne Paris Cité, France.
Anne BergerSimon Pernot, Geraldine Perkins, Julien Taieb, Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Paris Descartes, Sorbonne Paris Cité, France.
Julien TaiebSimon Pernot, Geraldine Perkins, Julien Taieb, Department of Gastroenterology and Digestive Oncology, Georges-Pompidou European Hospital, Paris Descartes, Sorbonne Paris Cité, France.
Hôpital Européen Georges-Pompidou · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the incidence of gastric cancer has decreased worldwide in recent decades, the incidence of signet-ring cell carcinoma (SRCC) is rising. SRCC has a specific epidemiology and oncogenesis and has two forms: early gastric cancer, which can be resected endoscopically in some cases and which has a better outcome than non-SRCC, and advanced gastric cancer, which is generally thought to have a worse prognosis and lower chemosensitivity than non-SRCC. However, the prognosis of SRCC and its chemosensitivity with specific regimens are still controversial as SRCC is not specifically identified in most studies and its poor prognosis may be due to its more advanced stage. It therefore remains unclear if a specific therapeutic strategy is justified, as the benefit of perioperative chemotherapy and the value of taxane-based chemotherapy are unclear. In this review we analyze recent data on the epidemiology, oncogenesis, prognosis and specific therapeutic strategies in both early and advanced SRCC of the stomach and in hereditary diffuse gastric cancer.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Signet Ring CellChemotherapy, AdjuvantDrug Resistance, NeoplasmGastrectomyHumansIncidenceNeoplasm StagingPredictive Value of TestsStomach NeoplasmsTreatment OutcomeCDH1Diffuse gastric cancerGastric cancerHereditary diffuse gastric cancerSignet ring cell carcinoma

Identifiers

PMID26523107
PMCPMC4616218
OpenAlexW2360734399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.